Jonathan Fleming is the President and CEO of Q-State Biosciences. Prior to joining Q-State Mr. Fleming had a 30 year venture capital career in starting, financing, and building neuroscience companies dedicated to drug discovery and development. Examples of companies he has been involved in starting and building include: Chairman of Synaptic Pharmaceuticals, which was acquired by Lundbeck; Chairman of Memory Pharmaceuticals, which was acquired by Hoffman La Roche; Chairman of Brain Cells; Chairman of Hypnion Pharmaceuticals which was acquired by Eli Lilly.
In addition Mr. Fleming's venture capital firm Oxford Bioscience Partners, of which he was the Managing Partner, was closely involved in the creation of the instrument by Solexa, subsequently sold to Illumina, that is used in high thru put sequencing throughout the world. Mr. Fleming's firm was also deeply involved in the creation of the high content screening market in the pharmaceutical industry by building Cellomics - now part of Thermo Fisher. Mr. Fleming was a lead director of the Board of Cellomics in the years prior to its acquisition. For the past ten years Mr. Fleming has taught the core course on life science strategy at the MIT Sloan School of Business. He is a director of Leerink Partners a highly regarded investment bank specializing in the life sciences as well as several other private life science companies.